Further to our letter dated May 14, 2026, whereby the Company had submitted the link of audio recording of the Q4 & FY26 Earning Conference Call on the Financial Results for the fourth ....
VIDHIING · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Vidhi Specialty Food Ingredients reported FY26 revenue of INR 380 crores (flat YoY) but saw strong margin improvement with EBITDA at INR 78 crores (20.52% vs 17.91% in FY25) and net profit of INR 49.15 crores (10.80% growth). Management guided that manufacturing EBITDA margins are around 24-25% currently, with value-added products contributing 5% of sales, expected to double to 10-12% in FY27. The company announced INR 75-85 crores capex for a new high-margin product line at Dahej (expected sales of INR 125-150 crores), commissioning in 18 months (mid-FY27-28), plus INR 5-12 crores for pharma CoatIcon range. Full capacity utilization expected across Dahej and Roha facilities in FY27. The company noted challenging geopolitical conditions impacting markets like Iran, Bangladesh, and Philippines, but expects demand recovery as conditions improve.
Strong margin performance despite revenue headwinds demonstrates operational resilience. The announced capex for new product lines signals meaningful growth ahead, though investors should note these will take 18 months to commission. Management's focus on value-added products (targeting 10-12% contribution in FY27) should support continued margin improvement.